What Pharmatech Associates does

Pharmatech Associates is a US-based consulting firm that provides specialized regulatory, quality, CMC, and manufacturing support to pharmaceutical, biotechnology, medical device, and combination product developers across the drug development lifecycle. Founded in 1995 as Pharmatech Validation Services and headquartered in San Ramon, California, the firm operates as the consulting arm of United States Pharmacopeia (USP) following its 2021 acquisition. Its service portfolio spans eight core offerings—Quality & Compliance, Regulatory Affairs, Product Development & CMC, Continuous Manufacturing, US Market Entry, Facilities Design & Validation, In Silico Modeling Services, and Due Diligence & In Licensing—applied across four therapeutic focus areas: Biologics & TIDES, Cell & Gene Therapies, Combination Products, and Small Molecules.

The firm's differentiated technology layer is its FDA-aligned In Silico CMC Modeling platform, delivered as Modeling-as-a-Service. The platform uses mechanistic and first-principles computational models to predict manufacturability, de-risk tech transfer and scale-up, and strengthen control strategies and shelf-life decisions. It supports model-informed FDA submissions and is positioned to reduce CMC development spend by 60% or more in select cases. The broader consulting methodology is anchored by senior practitioners with 20-40 years of industry experience across development, manufacturing, regulatory, and quality functions.

Pharmatech operates a professional services revenue model with quote-based engagements and employs an enterprise field sales motion. Lead generation is driven by thought leadership content and a Free Office Hours program that offers complimentary 30-60 minute sessions with senior consultants. The firm serves clients globally across North America, Europe, Asia, and Latin America, with delivery executed by experienced consultants under the USP umbrella. Revenue is not publicly disclosed, and the firm is a private, wholly-owned subsidiary of nonprofit USP with no external institutional investors.

Name

Pharmatech Associates

Legal name

Pharmatech Associates, Inc.

Website

https://pharmatechassociates.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharmatech Associates is a US-based consulting firm and consulting arm of United States Pharmacopeia that provides regulatory, quality, CMC, and manufacturing support to pharmaceutical, biotech, medical device, and combination product developers globally, with a differentiated FDA-aligned in silico modeling service.

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical consulting
• CMC regulatory affairs
• Quality compliance services
• In silico modeling
• Life sciences advisory

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Consulting Services: Pharmatech Associates generates revenue through professional consulting services delivered by subject matter experts. Services span CMC strategy, quality systems, regulatory affairs, facilities design, validation, due diligence, and in silico modeling. The company operates as an independent consulting organization under the USP umbrella.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Pharmatech Associates provides fee-based consulting services to pharmaceutical, biotechnology, medical device, and CDMO clients, covering Quality & Compliance, Regulatory Affairs, Product Development & CMC, Continuous Manufacturing, US Market Entry, Facilities Design & Validation, In Silico Modeling, and Due Diligence & In Licensing. Its teams apply regulatory expertise and proprietary FDA-aligned in silico CMC modeling to support tech transfer, scale-up, control strategy, and inspection readiness across small molecules, biologics, cell and gene therapies, and combination products.

Product overview

Pharmatech Associates, a USP company, offers a portfolio of consulting services organized around pharmaceutical product development and manufacturing support. The core service offerings include Quality & Compliance, Regulatory Affairs, Product Development & CMC, Continuous Manufacturing, US Market Entry, Facilities Design & Validation, In Silico Modeling Services, and Due Diligence & In Licensing. These services are applied across four product focus areas: Biologics & TIDES (monoclonal antibodies, biosimilars, peptides, oligonucleotides, ADCs), Cell & Gene Therapies, Combination Products, and Small Molecules. The integrated approach connects CMC strategy, regulatory execution, quality systems, and operational readiness from early development through commercial launch.

Differentiator

Problem solved

Functional benefit

Products and services

• Quality & Compliance Consulting service that designs and implements quality systems that scale with client programs, including QMS development, gap remediation, inspection readiness, and supplier oversight to ensure compliance at every stage for pharmaceutical, biotech, and medical device companies.
• Regulatory Affairs Expert regulatory strategy and execution from IND to approval, including pathway planning, submission preparation, and global agency engagement to accelerate timelines and reduce risk for pharma, biotech, and combination product developers.
• Product Development & CMC Integrated CMC strategies from early development through scale-up, including design of control strategies, tech transfer management, and regulatory alignment, for pharmaceutical and biotech companies commercializing small molecules and biologics.
• Continuous Manufacturing Design and implementation of efficient, compliant continuous manufacturing processes that improve quality, lower costs, and reduce environmental impact, including in-silico process and equipment optimization for pharmaceutical manufacturers and CDMOs.
• US Market Entry Preparation for successful FDA review and commercialization, bridging global-to-US regulatory gaps and supporting long-term market growth and manufacturing readiness for international pharma and biotech companies.
• Facilities Design & Validation Guidance from design through commissioning, qualification, and validation to achieve inspection readiness and operational success for new or expanded pharmaceutical, biotech, and CDMO facilities.
• In Silico Modeling Services AI-powered digital modeling delivered as Modeling-as-a-Service, leveraging FDA-aligned computational CMC modeling to reduce risk, compress timelines, and cut costs by anticipating CMC challenges before they surface for pharma and biotech programs.
• Due Diligence & In Licensing Technical and regulatory due diligence for drug substance, drug product, M&A, and in-licensing transactions, identifying risks and delivering clear strategies to protect and enhance deal value for investors and corporate deal teams.
• Biologics & TIDES Specialized consulting for monoclonal antibodies, biosimilars, bispecifics, peptides, oligonucleotides, and antibody-drug conjugates (ADCs), covering CMC, regulatory strategy, quality systems, and inspection readiness for biologics developers.
• Cell & Gene Therapies Support for advanced therapies including risk-based control strategies, regulatory alignment, and quality frameworks addressing the unique complexities of cell and gene therapy development for biotech and pharma developers.
• Combo Products Integration of drug, device, and biologic components into safe, compliant combination products with strategy and execution across human factors, regulatory pathways, and quality systems for combination product developers.
• Small Molecules Expertise in small molecule development including API and impurity control, robust specs and methods, supplier and data integrity, and CMC strategy supporting ANDA or 505(b)(2) requirements for small molecule developers.

Quantifiable outcome

• CMC development cost reduction of 60%+ in select cases
• +3 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

One partnership is on record.

• United States Pharmacopeia (USP)flagshipStrategic or Co-development Partner · 1 January 2021In 2021, Pharmatech Associates became the consulting arm of United States Pharmacopeia. USP is a globally recognized organization with over 200 years of history setting drug quality standards. Pharmatech complements USP's standards-setting work while operating as an independent consulting organization. Together, they share a single goal to help manufacturers bring safe, high quality medicines to patients.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ProPharma Group: ProPharma Group provides regulatory, compliance, and quality consulting for pharma, biotech, and medical device companies — directly comparable to Pharmatech's CMC/regulatory/quality service portfolio and similar mid-market positioning.
• BioProcess Technology Consultants (BPTC): BPTC specializes in CMC, bioprocess, and manufacturing sciences consulting for biologics and advanced therapies — a direct competitor in the same niche CMC consulting space as Pharmatech's Biologics & TIDES and Cell & Gene Therapy practices.
• Latham BioPharm Group: Latham BioPharm Group provides CMC, regulatory, and manufacturing consulting for life sciences companies — a like-sized direct peer that competes head-to-head on CMC strategy, regulatory affairs, and tech-transfer engagements.
• Pharmalex: Pharmalex delivers regulatory affairs, pharmacovigilance, and quality consulting across the product lifecycle — directly comparable to Pharmatech's Regulatory Affairs and Quality & Compliance service lines for pharma and biotech clients.

Broad incumbents

• Parexel International: Parexel is a global CRO with significant regulatory and CMC consulting capabilities. While far larger and broader in scope, it overlaps with Pharmatech on regulatory affairs and CMC strategy for pharma/biotech sponsors.
• IQVIA: IQVIA is a global life sciences technology and CRO leader offering regulatory, quality, and CMC consulting as part of a broader services portfolio. Competes with Pharmatech on enterprise pharma accounts but at vastly greater scale.
• Charles River Laboratories: Charles River provides discovery, safety assessment, and CDMO services with adjacent regulatory/CMC consulting. Overlaps with Pharmatech on biologics manufacturing support and regulatory strategy, but operates a much broader scientific services footprint.
• Deloitte (Life Sciences & Health Care practice): Deloitte's pharma and life sciences practice delivers regulatory, quality, and manufacturing transformation consulting at global scale. Competes with Pharmatech for enterprise pharma transformation programs and due diligence mandates.
• McKinsey & Company (Pharma & Medical Products practice): McKinsey's pharma practice advises on R&D productivity, regulatory strategy, and manufacturing excellence — competing for strategic advisory and due diligence mandates that also touch Pharmatech's investor and pharma client segments.

Emerging players

• Catalent: Catalent is a global CDMO with biologics and cell therapy capabilities. While primarily a manufacturer, it competes for technical-services mindshare in tech transfer and continuous manufacturing — adjacent rather than direct competition with Pharmatech's consulting model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmatech Associates